Keyword: akebia therapeutics
AZ expects COVID-19 to slow its growth. Health regulators warn of potential drug shortages. Akebia will use a priority review voucher on vadadustat.
11 would-be blockbusters span several therapeutic areas, including CNS, oncology, hematology, inflammatory diseases and metabolic disorders.
Samsung won FDA nod for a Remicade biosim, Otsuka expanded anemia deal with Akebia, analysts are cautiously optimistic about China's foreign drug proposal.